SITC 2021 | Early results from ONCR-177-101: ONCR-177 alone or in combination with anti-PD-1 blockade

Jong Chul Park, MD, Harvard Medical School, Boston, MA, gives an overview of the results of ONCR-177-101, a first-in-human Phase I study (NCT04348916) of intratumoral ONCR-177 alone or in combination with anti-PD-1 blockade in patients with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with liver metastases of solid tumors. ONCR-177 is an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes. Data from the dose-escalation and early dose expansion stages of the trial report a good safety profile, with no dose-limiting toxicities. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.